We read with interest the Review by Lyman and Sparreboom (Chemotherapy dosing in overweight and obese patients with cancer. Nat. Rev. Clin. Oncol. 10, 451-459; 2013) 1 because obesity is an area of inter est for oncologists owing to its association with increased risk of many cancer types. Compared with nonobese individuals, obese patients with cancer face a number of specific challenges related to the diagno sis and treatment of the disease. One such challenge is the optimal dosing of chemo therapy; uncertainties remain regarding toxicity and over dosing of chemotherapy in these patients. 1 In their article, Lyman and Sparreboom 1 discussed the evidence support ing the ASCO recom mendations for chemotherapy dosing in obese and over weight patients with cancer. 2 The authors acknowledged that chemo therapy dosing in adult patients with cancer is gener ally based on body surface area (BSA) and that obese patients receiving full chemotherapy doses do not experience more adverse events than healthy weight individuals. 1 However, we feel that the recommendations by ASCO to use actual body weight for chemotherapy dosing of overweight and obese cancer patients might not completely acknowledge all the available evidence.
One of the major confounding factors in the clinical approach to treating obese patients across different s ettings-i ncluding medical oncology-is the discrep ancy between the definition of obesity and how it is diagnosed in daily practice. The hallmark of obesity is the pathological increase of adiposity, yet obesity is generally diagnosed using BMI, which is calculated using only weight and height. 3 Thus, the complex ity of body compo sition changes is over looked and lost. It should be noted that BMI was originally developed for epidemio logical studies and its clinical relevance must be cautiously assessed when used for the assessment of individual patients. 3 Further complicating the clinical scenario in many obese patients is the observation that increased fat mass is associated with
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Alessandro Laviano, Serena Rianda and Filippo Rossi Fanelli sarcopenia, the loss of muscle mass. 4 The pathogenesis of sarcopenia is complex and related to the ageing process and to disease associated muscle wasting. 5 In the clinical setting, sarco penia is prevalent among obese patients with cancer and negatively impacts on clinical outcome. Prado et al. 6 showed that sarco penic obesity is an independent predictor of survival in obese adult patients with cancer. In the same study, the research ers observed that fatfree mass (FFM) has a poor association with BSA and estimated that variation in FFM among obese patients could result in up to threefold more varia tion in the effective volume of distribution for chemotherapy administered on the basis of BSA. 6 This variation suggests that sarco penic obesity is an unrecognized factor that can contribute to chemotherapyassociated toxic effects in obese patients.
Considering the clinical relevance of sarcopenic obesity, whether sarco penia or increased adiposity is related to chemotherapy related toxicity is impor tant to ascertain. Consistent data show that sarco penia predicts toxicity and compli cations in patients with cancer, treated with either drug regimens 7 or surgery, 8 and also in other diseases. 9 Thus, body composition analysis should be considered for inclusion in the general assessment of patients with cancer before starting chemo therapy. Many of the available tools for body composi tion analysis, such as anthropometry, bio impedance analysis and dualenergy Xray absorptiometry scans might not be highly accurate or affordable; 10 however, whole body CT scans, which many patients with cancer routinely undergo, can be used to easily and precisely measure muscularity. As correctly noted by Lyman and Sparreboom, 1 improvements in the tolera bility and efficacy of chemotherapy will emerge, hopefully soon, as a more personal ized approach to cancer treatment is implemen ted, taking into account a patient's genetic background and body composition. 1 The authors also acknowledge that ASCO clinical practice guidelines reflect the best evidence currently available. 2 Nevertheless, we feel that robust data already exist showing that sarcopenia is a negative prog nostic factor for treatmentassociated toxi city and, therefore, should be proactively assessed and treated early in all patients with cancer receiving anti tumour therapy. This suggestion is in agreement with the provisional clinical opinion issued by ASCO on the early inclusion of palliative care, of which nutrition therapy is central, in the management of patients with cancer. 12 
